Testing two drug combos for left-sided colon cancer
Part of Cancer, Digestive system clinical trials.
This trial compares two different chemotherapy combinations, both including a targeted therapy called cetuximab, as a first treatment for people with a specific type of advanced left-sided colon cancer that cannot be surgically removed. The goal is to find out which combination works better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your cancer must be on the left side of the colon and have spread to other parts of the body (metastatic).
- Your tumor must be a specific type: RAS and BRAF wild-type (no certain gene mutations) and MSS/pMMR (a certain genetic stability).
- You must not have had any prior chemotherapy or targeted therapy for advanced cancer, except for certain chemotherapy after surgery if it was more than 12 months ago.
- You must be in generally good health, able to perform daily activities (ECOG score 0 or 1).
- Your blood counts and organ function (kidney, liver) must be within adequate ranges as per study requirements.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a new combination of drugs (envafolimab, cetuxima-β, and chemotherapy) for people with a specific type of advanced colorectal cancer that has not been treated yet. The goal is to see if it is safe and works well.
This trial tests two different combinations of chemotherapy drugs plus targeted therapy (cetuximab or bevacizumab) along with an immunotherapy drug (QL1706) as the first treatment for people with left-sided metastatic colorectal cancer that has no mutations in the KRAS, NRAS, or BRAF genes. The goal is to see which combination is more effective and safe.
This Phase 2 trial tests a combination of medicines (cetuximab, envafolimab, and chemotherapy) as the first treatment for certain left-sided metastatic colorectal cancers. It may help by slowing or shrinking the cancer in people whose tumor has no RAS/BRAF mutations and is microsatellite-stable (MSS).
This Phase 2 trial tests whether adding cetuximab to irinotecan can control metastatic colorectal cancer that has returned or worsened after standard treatments. It targets people whose tumor is left-sided and shows “wild-type” RAS and BRAF genes on blood testing after prior therapy.
This trial tests whether adding an EGFR-targeting antibody to chemotherapy can help people with colorectal cancer that has spread to the liver. It's for those whose tumors have a normal RAS gene and who have not had treatment before.
This trial tests whether adding cetuximab to standard chemotherapy can improve outcomes for people with colorectal cancer that has spread only to the liver. It aims to see if the combination works better when specific tumor markers (RAS/BRAF) are “wild type” and the liver disease can be removed.
Hear when a new Colorectal Cancer (CRC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.